CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: RPC1063

First Posted Date: 2015-08-24

Last Posted Date: 2021-01-22

Lead Sponsor: Celgene

Target Recruit Count: 69

Registration Number: NCT02531113

Locations: 🇨🇦
LHSC Victoria Hospital, London, Ontario, Canada
🇺🇸
IMIC, Inc., Palmetto Bay, Florida, United States
🇺🇸
DM Clinical Research, Oak Lawn, Illinois, United States

and more 25 locations

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: RPC1063

First Posted Date: 2015-08-24

Last Posted Date: 2025-01-22

Lead Sponsor: Celgene

Target Recruit Count: 878

Registration Number: NCT02531126

Locations: 🇺🇸
Local Institution - 102, Anaheim, California, United States
🇺🇸
Local Institution - 179, Germantown, Tennessee, United States
🇺🇸
Local Institution - 143, Portland, Oregon, United States

and more 25 locations

An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide.

Completed

Conditions: Multiple Myeloma

First Posted Date: 2015-08-19

Last Posted Date: 2020-05-27

Lead Sponsor: Celgene

Target Recruit Count: 238

Registration Number: NCT02528838

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Lenalidomide

First Posted Date: 2015-08-13

Last Posted Date: 2019-11-08

Lead Sponsor: Celgene

Target Recruit Count: 28

Registration Number: NCT02521714

Locations: 🇺🇸
Covance-Daytona Beach, Daytona Beach, Florida, United States

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

Phase 1

Completed

Conditions: Pulmonary Fibrosis

Interventions: Drug: CC-90001

First Posted Date: 2015-07-29

Last Posted Date: 2017-04-04

Lead Sponsor: Celgene

Target Recruit Count: 16

Registration Number: NCT02510937

Locations: 🇺🇸
LaPorte County Institute for Clinical Research, Inc, Michigan City, Indiana, United States
🇺🇸
Tampa General Hospital, Tampa, Florida, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 3 locations

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: CC-122

First Posted Date: 2015-07-27

Last Posted Date: 2023-09-08

Lead Sponsor: Celgene

Target Recruit Count: 15

Registration Number: NCT02509039

Locations: 🇯🇵
Local Institution - 003, Chikusa-ku, Japan
🇯🇵
Local Institution - 001, Kashiwa, Japan
🇯🇵
Local Institution - 002, Koto-ku, Tokyo, Japan

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Phase 1

Terminated

Conditions: Healthy Volunteers
Parapsoriasis

Interventions: Drug: CC-90005
Drug: Placebo

First Posted Date: 2015-07-20

Last Posted Date: 2019-11-18

Lead Sponsor: Celgene

Target Recruit Count: 24

Registration Number: NCT02502188

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Phase 2

Completed

Conditions: Hematologic Malignancies
Neoplasms
Hematologic Neoplasm

Interventions: Drug: CC-486

First Posted Date: 2015-07-10

Last Posted Date: 2025-05-22

Lead Sponsor: Celgene

Target Recruit Count: 5

Registration Number: NCT02494258

Locations: 🇺🇸
Local Institution - 101, Gainesville, Florida, United States
🇺🇸
Local Institution - 103, Baltimore, Maryland, United States
🇺🇸
Local Institution - 102, Houston, Texas, United States

and more 1 locations

A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.

Phase 2

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Other: Control Arm
Drug: Azacitidine

First Posted Date: 2015-05-21

Last Posted Date: 2019-12-20

Lead Sponsor: Celgene

Target Recruit Count: 7

Registration Number: NCT02450877

Locations: 🇩🇪
Charite Berlin, Berlin, Germany
🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇪
Universitatsklinikum Essen, Essen, Germany

and more 5 locations

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Phase 2

Completed

Conditions: Leukemia, Myelomonocytic, Juvenile
Myelodysplastic Syndrome

Interventions: Drug: Azacitidine

First Posted Date: 2015-05-19

Last Posted Date: 2019-07-11

Lead Sponsor: Celgene

Target Recruit Count: 28

Registration Number: NCT02447666

Locations: 🇧🇪
Hopital Universitaire des Enfants, Brussels, Belgium
🇨🇭
Universitäts-Kinderklinik, Zurich, Switzerland
🇳🇱
Erasmus University Medical Center, Rotterdam, Netherlands

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy